Patent · US Active

Olopatadine formulations for topical nasal administration

US8399508B2 · kind B2 · utility

19Cited by

19References

2Claims

0Family size

Assignee

Alcon Pharmaceuticals, Ltd. · CH

Inventors

Onkar N. Singh · Arlington, US
G. Michael Wall · Fort Worth, US
Rajni Jani · Fort Worth, US
Masood A. Chowhan · Arlington, US
Wesley Wehsin Han · Arlington, US

Key dates

Filing date	Jun 30, 2011
Grant date	Mar 19, 2013
Priority date	—
Expiry date	Sep 28, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S424/81
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.